Author(s):
Taufik Mulla, Mrunali Nemade, Tahoora Ansari, Bhumika Parmar, Drashti Dave
Email(s):
mullataufik@gmail.com
DOI:
10.52711/0975-4377.2024.00026 
Address:
Taufik Mulla1*, Mrunali Nemade2, Tahoora Ansari3, Bhumika Parmar4, Drashti Dave5
1,5Krishna School of Pharmacy and Research, A Constituent College of Drs. Kiran and Pallavi Patel Global Univeristy, Varnama, Vadodara, Gujarat. India.
2,4Institute of Pharmaceutical Sciences, Parul University, Vadodara, Gujarat. India.
3Allana College of Pharmacy, A Constituent College of Dr. P.A. Inamdar University, Pune, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2024
ABSTRACT:
Omeprazole, a widely prescribed proton pump inhibitor renowned for its effectiveness in treating gastrointestinal disorders, faces limitations in its therapeutic potential due to its poor aqueous solubility, resulting in suboptimal bioavailability. This article conducts a thorough review of recent advancements in strategies aimed at enhancing omeprazole's solubility. The evaluation encompasses various techniques, including solid dispersion technology, nanosizing, cyclodextrin complexation, salt formation, and micellar delivery systems, all aimed at improving the solubility and overall therapeutic performance of omeprazole. The review addresses existing challenges and outlines future prospects, with a specific focus on the translation of solubility enhancement strategies from laboratory settings to commercial production. The comprehensive insights presented contribute to a profound understanding of the recent advancements in solubility enhancement of omeprazole, fostering the development of more efficient and patient-friendly formulations for improved therapeutic outcomes.
Cite this article:
Taufik Mulla, Mrunali Nemade, Tahoora Ansari, Bhumika Parmar, Drashti Dave. Advancements in Solubility Enhancement of Omeprazole: A Comprehensive Review. Research Journal of Pharmaceutical Dosage Forms and Technology.2024; 16(2):163-2. doi: 10.52711/0975-4377.2024.00026
Cite(Electronic):
Taufik Mulla, Mrunali Nemade, Tahoora Ansari, Bhumika Parmar, Drashti Dave. Advancements in Solubility Enhancement of Omeprazole: A Comprehensive Review. Research Journal of Pharmaceutical Dosage Forms and Technology.2024; 16(2):163-2. doi: 10.52711/0975-4377.2024.00026 Available on: https://rjpdft.com/AbstractView.aspx?PID=2024-16-2-7
REFERENCE:
1. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013; 9: 259-71. PMID: 23745048; doi: 10.2147/TCRM.S43151.
2. Huang JQ, Hunt RH. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996; 69: 159–174.
3. The American Society of Health-System Pharmacists. Archived from the original on 19 February 2011. Retrieved 21 October 2018.
4. Sachs G, Wallmark B. The gastric H+, K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol Suppl. 1989; 166:3-11.
5. Hassall E Barrett’s esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr. 1993; 16: 345-364.
6. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 1998 Sep; 12(9):893-7.
7. Wallmark B, Lindberg P: Mechanism of action of omeprazole. ISIS Atlas Pharmacol 1:158–160, 1987.
8. Narkhede, Pavan S., Namrata Singh, and Neetesh K. Jain. "Formulation And Characterization Of Immediate Release Solid Dosage Forms Of Omeprazole." Journal of Pharmaceutical Negative Results (2022): 4879-4883.
9. Haeney, M.R., 1992. Angio-edema and urticaria associated with omeprazole. BMJ: British Medical Journal, 305(6858), p.870.
10. Galindo, P.A., Borja, J., Feo, F., Gómez, E., Garcia, R., Cabrera, M. and Martinez, C.,. Anaphylaxis to omeprazole. Annals of Allergy, Asthma & Immunology. 1999; 82(1): 52-54.
11. Ghatan, P.H., Marcusson‐Ståhl, M., Matura, M., Björkheden, C., Lundborg, P. and Cederbrant, K., Sensitization to omeprazole in the occupational setting. Contact Dermatitis. 2014; 71(6): 371-375.
12. Kanagaratham, C., El Ansari, Y.S., Sallis, B.F., Hollister, B.M.A., Lewis, O.L., Minnicozzi, S.C., Oyoshi, M.K., Rosen, R., Nurko, S., Fiebiger, E. and Oettgen, H.C., Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice. Journal of Allergy and Clinical Immunology. 2020; 146(4): 884-893.
13. Darrow, J.J., Chong, J.E. and Kesselheim, A.S.,. Reconsidering the scope of US state laws allowing pharmacist substitution of generic drugs. BMJ. 2020; 369.
14. Xie, C., Liu, L., Zhu, S. and Wei, M. Effectiveness and safety of Chinese medicine combined with omeprazole in the treatment of gastric ulcer: A protocol for systematic review and meta-analysis. Medicine. 2021; 100(17).
15. Neuman, R.I., Baars, M.D., Saleh, L., Broekhuizen, M., Nieboer, D., Cornette, J., Schoenmakers, S., Verhoeven, M., Koch, B.C., Russcher, H. and van den Berg, S.A., Omeprazole administration in preterm preeclampsia: a randomized controlled trial to study its effect on sFlt-1 (soluble Fms-like tyrosine Kinase-1), PlGF (placental growth factor), and ET-1 (endothelin-1). Hypertension. 2022; 79(6): 1297-1307.
16. Llinas, A., Oprisiu, I. and Avdeef, A.,. Findings of the second challenge to predict aqueous solubility. Journal of Chemical Information and Modeling. 2020; 60(10): 4791-4803.
17. Van Nguyen, H., Baek, N. and Lee, B.J. Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion. International Journal of Pharmaceutics. 2017; 523(1):.189-202.
18. Pyo, Y.C., Nguyen, T.N., Lee, Y.S., Choi, Y.E. and Park, J.S. Design of esomeprazole solid dispersion for improved dissolution and bioavailability using the supercritical anti-solvent technique. Journal of Drug Delivery Science and Technology. 2023; 88: p.104889.
19. El-Badry, M. Comparative study of preparation and characterization of enteric and enhanced release omeprazole microparticles. Journal of Drug Delivery Science and Technology, 2011; 21(6): 491-496.
20. Chachlioutaki, K., Iordanopoulou, A., Bouropoulos, N., Meikopoulos, T., Gika, H., Ritzoulis, C., Andreadis, D., Karavasili, C. and Fatouros, D.G. Pediatric and Geriatric-Friendly Buccal Foams: Enhancing Omeprazole Delivery for Patients Encountering Swallowing Difficulties. Journal of Pharmaceutical Sciences. 2023; 112(10): 2644-2654.
21. Trimukhe, A., Rojekar, S., Vavia, P.R. and Deshmukh, R.R. Pulsed plasma surface modified omeprazole microparticles for delayed release application. Journal of Drug Delivery Science and Technology. 2021; 66: 102905.
22. Bunlung, S., Nualnoi, T., Issarachot, O. and Wiwattanapatapee, R. Development of raft-forming liquid and chewable tablet formulations incorporating quercetin solid dispersions for treatment of gastric ulcers. Saudi Pharmaceutical Journal. 2021; 29(10): 1143-1154.
23. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; .25(5): 588-600.
24. Halder, S., Tabata, A., Seto, Y., Sato, H. and Onoue, S. Amorphous solid dispersions of carvedilol along with pH‐modifiers improved pharmacokinetic properties under hypochlorhydoria. Biopharmaceutics and Drug Disposition, 2018; 39(4): 232-242.
25. Rouaz-El Hajoui, K., Herrada-Manchón, H., Rodríguez-González, D., Fernández, M.A., Aguilar, E., Suné-Pou, M., Nardi-Ricart, A., Pérez-Lozano, P. and García-Montoya, E.,. Pellets and gummies: Seeking a 3D printed gastro-resistant omeprazole dosage for paediatric administration. International Journal of Pharmaceutics. 2023; 643: 123289.
26. Negi, P., Gautam, S., Sharma, A., Rathore, C., Sharma, L., Upadhyay, N., Tambuwala, M.M., Chellappan, D.K., Gupta, G., Prasher, P. and Dua, K. Gastric ulcer healing by chebulinic acid solid dispersion-loaded gastroretentive raft systems: preclinical evidence. Therapeutic Delivery. 2022; 13(2):.81-93.
27. Gupta, K.M., Chin, X. and Kanaujia, P. Molecular Interactions between APIs and Enteric Polymeric Excipients in Solid Dispersion: Insights from Molecular Simulations and Experiments. Pharmaceutics. 2023; 15(4): 1164.
28. Peralta, C.M., Fernández, L.P. and Masi, A.N. Precision improvement for omeprazole determination through stability evaluation. Drug Testing and Analysis. 2012; 4(1):.48-52.
29. Trimukhe, A., Rojekar, S., Vavia, P.R. and Deshmukh, R.R. Pulsed plasma surface modified omeprazole microparticles for delayed release application. Journal of Drug Delivery Science and Technology. 2021; 66: 102905.
30. 8Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59: 1143–53.
31. Srebro, J., Brniak, W. and Mendyk, A. Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives. Pharmaceutics. 2022; 14(10): 2043.
32. Bell, N. J., Burget, D., Howden, C. W., Wilkinson, J. and Hunt, R. H. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992; 51(Suppl. 1): 59–67.
33. Vojčić, N., Bregović, N., Cindro, N., Požar, J., Horvat, G., Pičuljan, K., Meštrović, E. and Tomišić, V. Optimization of Omeprazole Synthesis: Physico‐Chemical Steering Towards Greener Processes. Chemistry Select. 2017; 2(17): 4899-4905.
34. Klieber, M., Oberacher, H., Hofstaetter, S., Beer, B., Neururer, M., Amann, A., Alber, H. and Modak, A. CYP2C19 phenoconversion by routinely prescribed proton pump inhibitors omeprazole and esomeprazole: clinical implications for personalized medicine. Journal of Pharmacology and Experimental Therapeutics. 2015; 354(3): 426-430.
35. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; 25(5): 588-600.
36. Gupta, M.K., Sreedharan, S.K. and Sajeeth, C.I. Design development and characterization of omeprazole loaded nanosuspension. Journal of Pharmaceutical Negative Results, 2022: 1195-1208.
37. Rezazadeh, M., Safaran, R., Minaiyan, M. and Mostafavi, A. Preparation and characterization of Eudragit L 100-55/chitosan enteric nanoparticles containing omeprazole using general factorial design: in vitro/in vivo study. Research in Pharmaceutical Sciences. 2021; 16(4): 358.
38. Ramteke, S. and Jain, N.K. Clarithromycin-and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori. Journal of Drug Targeting. 2008; 16(1):.65-72.
39. Le Merdy, M., Tan, M.L., Sun, D., Ni, Z., Lee, S.C., Babiskin, A. and Zhao, L. Physiologically based pharmacokinetic modeling approach to identify the drug–drug interaction mechanism of Nifedipine and a proton pump inhibitor, Omeprazole. European Journal of Drug Metabolism and Pharmacokinetics. 2021; 46: 41-51.
40. Murakami, F.S., Lang, K.L., Mendes, C., Cruz, A.P., Carvalho Filho, M.A. and Silva, M.A. Physico-chemical solid-state characterization of omeprazole sodium: thermal, spectroscopic and crystallinity studies. Journal of Pharmaceutical and Biomedical Analysis. 2009; 49(1): 72-80.
41. Gao, H., Song, Y., Ma, J., Zhai, J., Zhang, Y. and Qu, X. Untargeted metabolomics analysis of omeprazole-enhanced chemosensitivity to cisplatin in mice with non-small cell lung cancer. Chemico-Biological Interactions. 2022; 360: 109933.
42. Gupta, M.K., Sreedharan, S.K. and Sajeeth, C.I., Design development and characterization of omeprazole loaded nanosuspension. Journal of Pharmaceutical Negative Results. 2022; 1195-1208.
43. Boscolo, O., Perra, F., Salvo, L., Buontempo, F. and Lucangioli, S. Formulation and stability study of omeprazole oral liquid suspension for pediatric patients. Hospital Pharmacy. 2020; 55(5): 314-322.
44. Yadollahi, R., Vasilev, K. and Simovic, S., 2015. Nanosuspension technologies for delivery of poorly soluble drugs. Journal of Nanomaterials. 2015: 1-1.
45. Bestebreurtje, P., Roeleveld, N., Knibbe, C.A., van Sorge, A.A., Plötz, F.B. and de Wildt, S.N. Development and stability study of an omeprazole suppository for infants. European Journal of Drug Metabolism and Pharmacokinetics. 2020; 45: 627-633.
46. Neishi, M., Hamano, H., Niimura, T., Denda, M., Yagi, K., Miyata, K., Lin, T.J., Higashionna, T., Goda, M., Zamami, Y. and Ishizawa, K. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases. Toxicology and Applied Pharmacology. 2023; 475: 116632.
47. Sardesai, S.D., Thomas, A., Gallagher, C., Lynce, F., Ottaviano, Y.L., Ballinger, T.J., Schneider, B.P., Storniolo, A.M., Bauchle, A., Althouse, S.K. and Perkins, S.M. Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC. Clinical Cancer Research, 2021; 27(21): 5810-5817.
48. Arias, M.J., Arias-Blanco, M.J., Moyano, J.R., Muñoz, P., Gines, J.M., Justo, A. and Giordano, F. Study of omeprazole-γ-cyclodextrin complexation in the solid state. Drug Development and Industrial Pharmacy. 2000; 26(3): 253-259.
49. Sultana, T., Jung, J.M., Hong, S.S., Lee, W.K., Gal, Y.S., Kim, H.G. and Lim, K.T. Characteristic profiles of the inclusion complex of omeprazole/peracylated-β-cyclodextrin formed in supercritical carbon dioxide. Journal of Inclusion Phenomena and Macrocyclic Chemistry. 2012; 72: 207-212.
50. Setiadji, S., Sundari, C.D.D., Nuryadin, B.W., Zayyinunnisya, H., Cahyandari, R. and Ivansyah, A.L. September. Computational Study of Inclusion Complexes Between Omeprazole Enantiomer with Hydroxypropyl-β-Cyclodextrin. In Journal of Physics: Conference Series. 2018; 1090(1): 12055
51. Bestebreurtje, P., Roeleveld, N., Knibbe, C.A., van Sorge, A.A., Plötz, F.B. and de Wildt, S.N. Development and stability study of an omeprazole suppository for infants. European Journal of Drug Metabolism and Pharmacokinetics. 2020; 45: 627-633.
52. Strotmann, R., Heuer, J., Becker, A., Krebs-Brown, A., Mammasse, N. and Yalkinoglu, Ö. Bioavailability of tepotinib: impact of omeprazole and food. Annals of Oncology. 2019; 30: 182.
53. Washington, C., Hou, E., Hughes, N. and Berner, B. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. American Journal of Health-System Pharmacy. 2006; 63(7): 653-656.
54. Spénard, J., Aumais, C., Massicotte, J., Tremblay, C. and Lefebvre, M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. The Journal of Clinical Pharmacology. 2004; 44(6): 640-645.
55. Arias, M.J., Arias-Blanco, M.J., Moyano, J.R., Muñoz, P., Gines, J.M., Justo, A. and Giordano, F. Study of omeprazole-γ-cyclodextrin complexation in the solid state. Drug Development and Industrial Pharmacy. 2000; 26(3): 253-259.
56. Cross, L.B. and Justice, L.N. Combination drug therapy for gastroesophageal reflux disease. Annals of Pharmacotherapy. 2002; 36(5): 912-916.
57. Freston, J.W. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. American Journal of Gastroenterology (Springer Nature). 1997: 92.
58. Setiadji, S., Sundari, C.D.D., Ramdhani, M.A., Umam, A.B.K. and Ivansyah, A.L. Theoretical investigation of inclusion complex between omeprazole enantiomers and carboxymethyl-β-cyclodextrin. In IOP Conference Series: Materials Science and Engineering. 2018; 288(1); 12138.
59. Ferreira, J. and Moss, S.F. Current paradigm and future directions for treatment of Helicobacter pylori infection. Current Treatment Options in Gastroenterology. 2014; 12: 373-384.
60. Figueiras, A., Carvalho, R.A., Ribeiro, L., Torres-Labandeira, J.J. and Veiga, F.J. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics. 2007; 67(2): 531-539.
61. Åsberg, D., Leśko, M., Samuelsson, J., Karlsson, A., Kaczmarski, K. and Fornstedt, T. Combining chemometric models with adsorption isotherm measurements to study omeprazole in RP-LC. Chromatographia. 2016; 79: 1283-1291.
62. Vrbanec, T., Šket, P., Merzel, F., Smrkolj, M. and Grdadolnik, J. Spectroscopic characterization of omeprazole and its salts. Journal of Spectroscopy. 2017.
63. Shastry, V., Ramyashree, H. and Ravindra, K. Kinetics and mechanism of oxidation of omeprazole by potassium ferrate. International Journal of Medicince and Pharmaceutical Science. 2019; 9: 9-18.
64. Rajana, Nagaraju. Srikanth, B., Ramana, D.V., Yarbagi, K.M., Madhavan, P., Babu, J.M., Basavaiah, K. and Devi, D.R. Simultaneous Determination of Sodium, Potassium and Magnesium Counter Ions in Three Drugs: Pantoprazole Sodium, Losartan Potassium and Omeprazole Magnesium by Ion Chromatography. Asian J Chemistry. 2018; 30(9): 2022-2028.
65. Strotmann, R., Heuer, J., Becker, A., Krebs-Brown, A., Mammasse, N. and Yalkinoglu, Bioavailability of tepotinib: impact of omeprazole and food. Annals of Oncology. 2019; 30: 182.
66. Figueiras, A., Carvalho, R.A., Ribeiro, L., Torres-Labandeira, J.J. and Veiga, F.J. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin. European Journal of Pharmaceutics and Biopharmaceutics. 2007; 67(2): 531-539.
67. Zheng, R.N. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World Journal of Gastroenterology. 2009; 15(8): 990.
68. Boscolo, O., Perra, F., Salvo, L., Buontempo, F. and Lucangioli, S. Formulation and stability study of omeprazole oral liquid suspension for pediatric patients. Hospital Pharmacy. 2020; 55(5): 314-322.
69. Klein, L.L. and Tanaka, S.K. Therapy of Helicobacter pylori infections: Current status and future directions. Annual Reports in Medicinal Chemistry. 1995; 30: 151-158.
70. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; 25(5): 588-600.
71. Al-Nimry, S.S., Alkhamis, K.A. and Altaani, B.M. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Pharmaceutical Development and Technology. 2020; 25(5): 588-600.
72. Lopes-de-Campos, D., Pereira-Leite, C., Fontaine, P., Coutinho, A., Prieto, M., Sarmento, B., Jakobtorweihen, S., Nunes, C. and Reis, S. Interface-Mediated Mechanism of Action—The Root of the Cytoprotective Effect of Immediate-Release Omeprazole. Journal of Medicinal Chemistry. 2021; 64(8): 5171-5184.
73. Sinly, C., Saito, H., Anorach, R., Uramaru, N., Kaku, T., Benchawattananon, R., Navanukraw, C., Panomsuk, S., Kubota, Y. and Rittirod, T., Stability consideration in extemporaneous omeprazole suspension.
74. Cong, Y., Geng, J., Wang, H., Su, J., Arif, M., Dong, Q., Chi, Z. and Liu, C. Ureido-modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in vitro evaluation. International journal of biological macromolecules. 2019; 129: 686-692.
75. Aubert, J., Mulder, C.J., Schrör, K. and Vavricka, S.R. Omeprazole Mups®: An advanced formulation offering flexibility and predictability for self medication-Selfcare Journal. SelfCare Journal. 2015.
76. Zheng, R.N. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World Journal of Gastroenterology. 2009; 15(8): 990.
77. Markovic-Pekovic, V., Škrbić, R., Godman, B. and Gustafsson, L.L. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Review of Pharmacoeconomics and Outcomes Research, 2012; 12(5): 661-671.
78. Franciosi, J.P., Mougey, E.B., Dellon, E.S., Gutierrez-Junquera, C., Fernandez-Fernandez, S., Venkatesh, R.D. and Gupta, S.K. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. Journal of Asthma and Allergy. 2022: 281-302.